Loading
Led CheckMate 816, which established neoadjuvant chemo-immunotherapy for resectable lung cancer.
Patrick M. Forde is Director of the Thoracic Oncology Clinical Research Program at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is known for pioneering neoadjuvant PD-1 blockade in resectable non-small-cell lung cancer, from a 2018 pilot study to leading the CheckMate 816 phase 3 trial that established neoadjuvant nivolumab plus chemotherapy as a standard. His selected papers report neoadjuvant PD-1 blockade in resectable lung cancer and neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. He also leads mesothelioma trials.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant PD-1 blockade in resectable lung cancer | New England Journal of Medicine | 2018 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer | New England Journal of Medicine | 2022 |
Shares CheckMate 816, CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Resectable stage I to III non-small-cell lung cancer, Nivolumab.
Shares CheckMate 816, CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Resectable stage I to III non-small-cell lung cancer, Nivolumab.
Shares CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Mesothelioma, Nivolumab.
Shares CheckMate 816, Mesothelioma, Non-small-cell lung cancer.
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Nivolumab, PD-1, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, PD-1, Non-small-cell lung cancer.
Shares CheckMate 816, Resectable stage I to III non-small-cell lung cancer, PD-1.
Shares Mesothelioma, Nivolumab, PD-1.